TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from RemeGen Co. Ltd. Class H ( (HK:9995) ) is now available.
RemeGen Co., Ltd. has announced its 2024 Annual General Meeting (AGM) scheduled for June 26, 2025, where shareholders will consider and approve various resolutions. The agenda includes approving the 2024 financial accounts, profit distribution plan, and re-appointment of accounting firms, as well as special resolutions like issuing additional shares and amending company regulations. These decisions are pivotal for the company’s strategic direction and governance structure, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company focuses on the development and commercialization of innovative biologics, particularly in the areas of oncology and autoimmune diseases.
Average Trading Volume: 9,367,111
Technical Sentiment Signal: Buy
Current Market Cap: HK$31.81B
For an in-depth examination of 9995 stock, go to TipRanks’ Stock Analysis page.